Becton Dickinson Stock - Analyst consensus and valuation snapshot

Edited by ad hoc news Long-Term & Business-Model Desk. Verified prior to publication on 06/20/2026, 15:52 UTC. Details in the imprint.

Becton, Dickinson and Company (US0758871091) remains a core name in global medical technology. Analyst estimates, valuation metrics and the next earnings date frame how investors currently look at the stock, based on recent data from major financial platforms.

What recent figures show

On MarketBeat, Becton, Dickinson and Company stock last closed at about $143.99 on the New York Stock Exchange on 06/18/2026, with extended trading around $143.01 that evening. MarketBeat quotes for BDX

The same data set points to a market capitalization in the mid tens of billions of dollars, underlining the company's role as a large-cap medtech name in the Standard & Poor's 500 index. This places Becton Dickinson among the more defensive healthcare holdings.

Analyst consensus and ratings

Analyst roundups compiled by MarketBeat describe Becton Dickinson as a widely covered stock, with several major Wall Street houses providing ratings and price targets. MarketBeat analyst overview for BDX

The consensus rating in these summaries tends to fall into the Buy or Moderate Buy range, with target prices that sit noticeably above the recent share price. Exact figures can shift quickly as new quarterly results and guidance changes come in.

Long-term drivers and earnings

According to the company's own investor materials, Becton Dickinson focuses on steady, recurring revenue streams from disposable products and capital equipment across hospitals, laboratories and life science customers. BD investor presentation and filings

Next earnings dates are generally published well in advance on the investor relations calendar, giving the market clear focal points several times a year. Against this backdrop, earnings quality and cash flow remain central to how analysts frame the stock over the long run.

How the company makes money

Becton Dickinson generates most of its revenue from medical supplies, devices, laboratory equipment and diagnostic systems. Core offerings span needles, syringes, infusion products, blood collection systems, molecular diagnostic platforms and other solutions used daily in clinical and research settings.

Where the stock trades today

The shares of Becton, Dickinson and Company (US0758871091) trade on the New York Stock Exchange at approximately $143.99 as of 06/18/2026, 15:59 Eastern Time.

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.